| Followers | 26 |
| Posts | 2781 |
| Boards Moderated | 0 |
| Alias Born | 03/18/2013 |
Friday, February 24, 2017 11:24:51 AM
I'm limited to one post per day (Indefinitely)..... so, I have to make each message count....I can't respond to anyone until the next day.
#1 - Thanks SAM81, the numbers look great, finally broke 20K weekly scripts. Amarin should be getting close to being cash flow positive???
#2 - HDGabor, the $9 coupon is all fine and good for those not on Express Scripts. Last time I checked Express Scripts has VASCEPA listed as a "Maintenance Drug" not a "Preventive drug". If it was a Preventive Drug then things would be different. Regardless, I cannot get a co-pay which I can reasonably afford. I pay full price for VASCEPA plain and simple. After beating your head trying to get people to listen and provide information one gives up..... the insurance companies continue to play these games. No where can I get the tie in between United Health Care and Express Scripts. UHS has Vascepa as a Preventive Drug, whereas Express Scripts does not, even though both companies are affiliated, although not on paper. I cannot get a script filled through UHS as they refer me to Express Scripts. :D(
#3 - I'm 65, not retired and not currently on Medicare as I'm still working (on Obamacare) and have to provide for a minor child. Now unless someone out there knows how this Medicare stuff works...then I'm all ears. To me it's like reading the US Tax Code.
#1 - Thanks SAM81, the numbers look great, finally broke 20K weekly scripts. Amarin should be getting close to being cash flow positive???
#2 - HDGabor, the $9 coupon is all fine and good for those not on Express Scripts. Last time I checked Express Scripts has VASCEPA listed as a "Maintenance Drug" not a "Preventive drug". If it was a Preventive Drug then things would be different. Regardless, I cannot get a co-pay which I can reasonably afford. I pay full price for VASCEPA plain and simple. After beating your head trying to get people to listen and provide information one gives up..... the insurance companies continue to play these games. No where can I get the tie in between United Health Care and Express Scripts. UHS has Vascepa as a Preventive Drug, whereas Express Scripts does not, even though both companies are affiliated, although not on paper. I cannot get a script filled through UHS as they refer me to Express Scripts. :D(
#3 - I'm 65, not retired and not currently on Medicare as I'm still working (on Obamacare) and have to provide for a minor child. Now unless someone out there knows how this Medicare stuff works...then I'm all ears. To me it's like reading the US Tax Code.
Recent AMRN News
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:04 AM
- Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization • GlobeNewswire Inc. • 01/09/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2026 12:05:27 PM
- Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities • GlobeNewswire Inc. • 01/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:17 PM
